Known in the US as Lou Gehrig's disease, after the legendary American baseball first baseman . ALS progresses rapidly and is invariably fatal. ALS afflicts some 350,000 people a year worldwide, with a prevalence of 2-4 per 100,000 individuals.
Before the age of 65, slightly more men than women develop ALS, with the only striking female predominance appearing in bulbar-onset patients. This sex difference disappears after age 70 [1] [2] [3] . There is no curative treatment, and the drugs currently available have an imperceptible action on the clinical course [4] .
ALS was described for the first time 140 years ago [5] . Despite the identification of several single gene mutations with more than 10 loci, mostly in autosomal dominant familial cases (fALS), ALS is a multisystem neurodegenerative disease whose origin and progression are not clearly understood [6] . For the familial forms, fifteen years after the initial discovery of mutations in the enzyme Cu/Zn superoxide dismutase (SOD1), a diversity of new genetic mutations have been progressively identified, including TAR DNA binding protein-43 (gene TARDBP, protein TDP-43) and the C9orf72 gene, until now the most common mutation underlying fALS. Recent data from family histories suggest a continuum of heritability between fALS and sporadic ALS (sALS), with a progressive decrease in the frequency of mutations in ALS genes [7, 8] .
Except for the rare juvenile form (especially the very aggressive fused in sarcoma (FUS) gene mutation form [9] ) the age range for developing ALS is quite broad, between 45 and 60 years [10] . The progressive atrophy and loss of upper (corticospinal) and lower (spinal and bulbar) specialized neurons lead to muscle atrophy, weakness and spasticity, and rapidly to paralysis [11] . In a diversity of phenotypes, the extrapyramidal, cerebellar, sensory or autonomic systems are also affected [12] . (See per cent of ALS patients who develop frontotemporal dementia (FTD), adds another dimension the disease's genetic and phenotypic variability [14] [15] [16] [17] . Together with its large clinical heterogeneity (Figure 1a ) even within the familiar forms [18] [19] [20] the absence of specific biomarkers delays ALS diagnosis and strongly limits an early neuronal therapeutic approach.
Until now, the higher ALS prevalence in specific groups of patients (football players [21] [22] [23] , veterans of the Gulf War [24, 25] or farmers with elevated pesticide and/or fertilizer exposure [26] [27] [28] [29] ) has not helped unravel the cascade of events or the driving force underlying the disease. Several pathological mechanisms such as genetic factors, environment, autoimmunity, oxidative stress, excitotoxicity, microglial activation, impairment in filament organization and neuronal transport, and misfolded proteins have been proposed as possible explanations of ALS heterogeneity [30, 31] . Among them, misfolded protein aggregation and neuroinflammation are the only common mechanisms present in most ALS patients (Figure 1b) . The recent implication of microglia in non-inflammatory functions challenges our concept of neuroinflammation and opens up new avenues in the study of ALS pathophysiology. In this review we discuss the current knowledge of these mechanisms, placing special emphasis on the non-inflammatory dynamic interactions between neurons and microglia in ALS.
GENETICS OF ALS
The hunting for genetic mutations causative for ALS has accumulated substantial body of research, with a wide range of results. According to the ALSoD database [32] , 126 genes had been associated with ALS by September 2015. Of these, defects in six genes have been found to be main causes of the disease [33] , and a growing number of genes have been associated with ALS susceptibility, progression or prevalence. [34] [35] [36] [37] [38] ( Table 1 ) Multiple mutations of a sole gene also lead to graded phenotypic affectations.
For example, the 166 widely dispersed exonic mutations of the Cu/Zn superoxide dismutase (SOD1) gene coding for a mitochondrial enzyme of only 153 amino acids that neutralize toxic superoxide radicals are associated with some 20% of fALS and 1-3% of sALS, all characterized by a large heterogeneity in their presentation [39] [40] [41] [42] [43] .
However, toxicity of SOD1 exon mutations is related not to altered enzyme activity but to the formation of SOD1 misfolded protein aggregates [44] [45] [46] [47] . Characterized in motor neurons and glial cells, wild-type and mutant SOD1 aggregates [39, 48] correlate with a similar ALS phenotype [49, 50] and also in mice with wild-type SOD1 causing ALS [51] . Inflammation and neuronal death represent a cascade events that are also present in other neurodegenerative diseases characterized by misfolded protein aggregates like the protease-resistant prion protein, Amyloid-β, Tau, or α-synuclein [52, 53] .
This toxic formation of protein aggregates applies to many other native and mutated misfolded proteins characterized in ALS patients, like the vesicle associated membrane protein (VAMP)-associated protein (VAPB), TARDBP, FUS, and angiotensin (ANG) genes [33, 54] , and has been extended by the discovery of frequent combined C9orf72 gene mutations that facilitate native protein aggregation (see below). The recently discovered TBK1 gene mutations modify two main pathways, inflammation and autophagy [55] , and may alter microglial adaptation to neuronal damage, in particular the engulfment of dying spinal cord neurons [56] .
Different VAPB mutations combined with other ALS-relevant mutations, like those in C9orf72 [57, 58] [59, 60] .
The recent discovery in patients with and without fALS history that the C9orf72 gene defect can cause ALS [61, 62] has added a new dimension to the disease's complexity. It challemged the present fALS and sALS classification (Figure 1b) , and offered a convergent explanation of ALS pathogenesis that includes RNA dys-metabolism and proteinopathy [63] . In fact, the common genetic variations found in both genetic and sporadic ALS patients by genome-wide association studies [64, 65] include a diversity of factors that support ALS susceptibility and heterogeneity, and argue for subgroups of both fALS and sALS along an ALS continuum.
ALS AS A MISFOLDED PROTEIN DISEASE
The genetic data suggest that alterations in RNA processing (modified protein synthesis) and proteinopathy (modified protein degradation) are key to both fALS and sALS pathogenesis. For example, 97% of all sporadic cases present TDP-43 proteinopathy, characterized by cytoplasmic TDP-43 ubiquitinated aggregates [66] . In 45% of all sporadic FTD cases, and in numerous genetic mutations of fALS-FTD, TDP-43 proteinopathy also occurs [16, 67] . Multiple forms of ALS may then be viewed as different manifestations of a misfolded protein disease (MPD), in which a misfolded protein like SOD1, VAPB or TDP-43 develops insidiously and initiates an early neurodegenerative process that manifests clinically in middle or late life in both sALS and fALS.
In all MPDs, the pathogenic mechanism represents the initial aggregation and CNS deposition of a misfolded protein in specific neurons and/or astroglia that grow following a crystallization-like process [68] [69] [70] Elaborate systems have evolved to protect cells from misfolded proteins. An example is the ubiquitin-proteasome system, which degrades the newly translated proteins that failed to fold correctly [72, 73] . In PMD, misfolded proteins are not removed and they aggregate within the cell. As seen in the frontal cortex and spinal cord from sALS patients and in the SOD1 G93A spinal cord in mice, these aberrant intracellular accumulations result in ER stress, proteasomal impairment and increased energy demand, progressive Golgi damage, and mitochondrial dysfunction with massive oxidative stress [53, [74] [75] [76] . In addition, these aggregates from dying neurons/astrocytes or mediated by exosomes activate a microglial phagocyte phenotype to remove aggregates and cellular debris [77, 78] (figure 2) and extends the damage to the surrounding cells mostly via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated excitotoxicity in spinal motor neurons [79] . Similar results are observed with the Guam population diet which is rich in β-methyl-amino-L-alanine (BMAA). It chronically activates AMPA receptors, and in combination with other insults or with genetic predisposition, leads to ALS [80, 81] . Glia participation in the neurodegenerative process depends on increased energy consumption [82, 83] . Increased energy consumption is also required for neurons to engulf aggregates, repair damage or enter in apoptosis [84] [85] [86] . In these conditions, glucose transport to CNS is not sufficient to cover demand, and lactate is formed within astrocytes and sent to neurons for its complete oxidation [87, 88] . As a result, the tissue pH decreases, which alters protein folding and induces aggregate formation, as observed with Amyloid-β [89] . In ALS, this dynamic adaptation of the glial phenotype to the graded metabolic and structural modifications results in an overproduction of neurotoxic molecules and chronic neuroinflammation ( Figure 2 ) which drives, at least in part, the disease progression [77, [90] [91] [92] .
The pleiotropy of the ALS genes coding for proteins involved in this pathogenic process represents, in fact, a convergent mechanism that helps explain the broad spectrum and peculiar complexity of ALS clinical manifestations [93] . The presence of alterations in interrelated metabolic pathways has also been confirmed by blood analysis of ALS patients [94] . Currently, there is a growing consensus among clinicians and researchers that the degeneration and death of upper and lower motor neurons relies on the convergence of various altered metabolic processes in which neuroinflammation is always present and related with high energy consumption and misfolded protein formation ( Figure 1b ). For these reasons, energy metabolism and nutritional status are factors that help to explain the penetrance variability of ALS genes [95, 96] 
ENERGY METABOLISM AND NUTRITION IN ALS
Whole body energy metabolism is impaired in ALS, and body mass index and overall nutritional status at disease onset are independent predictors of survival in ALS [94] . A recent metabolomics study identified alterations characteristic of an increased glycolysis and lipolysis in order to produce more adenosine triphosphate (ATP) and thus to facilitate energy consuming processes [97] . This overall increase in energy demand reflects major cellular activity in an atempt to control the ALS neurodegenerative process taking place and to activate CNS and muscle repair. To ensure very high levels of ATP production from carbohydrate and lipid oxidation, mitochondria increase their activity and number, resulting in enhanced release of reactive oxygen species (ROS) [98] . In close contact with the nucleus, which also produces ATP from the ADP-ribosyl residues after sudden extensive changes in chromatin [99] (perhaps the ones caused by the heterogeneous ribonucleoproteins (hnRNPs) identified in ALS) proteasome becomes especially important for maintaining cellular homeostasis through degradation of ubiquitinated factors like Drp1, which control mitochondria fusion and fission and the ubiquitinated misfolded ALS proteins [100] . In addition, reduced glucose uptake and metabolism consequent to increased glucocorticoid signaling pathways cannot be discarded [101] [102] [103] .
In fact, the on-going ALS neurodegenerative process is the result of two dynamic tissue mechanisms, one neurotoxic and an adaptive neuroprotective. The high-energy demand present in ALS must be part of this second mechanism, which remains efficient despite its elevated ROS production and progressive mitochondria and proteasome damage, and the altered ER-mitochondria interactions. In any case, the importance of rich-energy nutrition must be considered a key aspect of the patient care. In this framework, the Guam population, whose etiology of ALS correlates significantly with picking, processing, and eating cycad seed flour rich in neurotoxins such as BMAA, a potent glutamate agonist at both AMPA and kainate receptors [104] exemplifies the relevance of nutritional factors [105, 106] . As such recent clinical trials have highlighted the importance of controlling ALS patient nutrition, with interventions from 
REFINING CONTROL OF NEUROINFLAMMATION IN ALS
Until a few years ago, little was known about microglia adaptation and participation in ALS, and the microglia's direct and permanent involvement in the disease is a recent discovery. ALS pathophysiology includes a chronic microglial reaction in the surroundings of degenerative motor neurons [107] . In patients with ALS, microgliosis appears specifically in the motor cortex, along the corticospinal tract, and in the ventral horn of the spinal cord [108] [109] [110] . Although the molecular mechanisms of this neuroinflammation have not been clarified, it has been demonstrated that activation of microglia in the ALS-injured CNS leads to release of cytokines, chemokines, and neurotrophic or neurotoxic factors that stimulate astrocytes and mobilize cells from the peripheral immune system [111] [112] [113] . These cells in turn produce new cytokines creating a chronic inflammatory response [111, 112] .
In the healthy CNS, microglia present a highly ramified morphology, express receptors for neurotransmitters and neuromodulators [116] [117] [118] , dynamically monitor the neuronal microenvironment and actively respond to neuronal activity as an integrated part of the "quad-partite" synapse [119] [120] [121] . This non-inflammatory microglial activity has important roles in CNS development eliminating the excess of neurons and controlling synaptic pruning and maturation of excitatory synapses (see [122] for a review). In the adult brain, the microglia is an important player in the regulation of synaptic plasticity [121, 123, 124] and in clearing newborn adult hippocampal progenitors [125] . Thus, there is evidence of the involvement of microglia in the control of long-term potentiation [126] [127] [128] long-term depression [129] , synaptogenesis [130, 131] , and in sensing and eliminating defunct synapses [119] .
These non-inflammatory roles of microglia involve dynamic interactions with neurons.
Microglia are maintained in surveillance via signaling between fractalkine (CX3CL1) and its G-coupled protein receptor, CX3CR1. In the CNS, fractalkine is expressed by neurons as a membrane-bound glycoprotein, from which a soluble chemokine can be proteolytically released [132, 133] . Fractalkine modulates migration, motility, and activation of microglia by interaction with the CX3CR1, which is specifically expressed in microglia [112] . In turn, the interaction fractalkine-CX3CR1 is required for proper maturation of excitatory synaptic transmission [134] ; mice lacking CX3CR1 show persistent alterations in hippocampal glutamatergic transmission [135] .
When microglia become reactive, their morphology changes, ranging from enlargement of processes and hypertrophy of the cell body to acquisition of an amoeboid shape.
Besides these morphological alterations, reactive microglia also release cytokines and upregulate a variety of surface molecules [113, [136] [137] [138] . Classically, microglia have been considered as resident macrophages of the CNS and the concept of macrophage polarization has been extrapolated to explain reactive microglia activity [139] .
According to this paradigm, M1 (or classically activated) microglia present inflammatory activity, whereas M2 (or alternatively activated) microglia have tissue repair functions [107] . Initially a pro-inflammatory M1 phenotype aims to protect and repair damaged tissue but prolonged and excessive inflammation is cytotoxic and induces neuronal death [136] [137] [138] . Pro-inflammatory microglia promote a neurotoxic Tcell response and are cytotoxic owing to the secretion of nitric oxide (NO) and classical pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, ROS production and the reduction of protective trophic factor expression F o r R e v i e w O n l y 11 [142] . In addition, chronically activated microglia may become increasingly dysfunctional and may directly participate in the development of secondary tissue injury [143] . In contrast, M2 neurorestorative microglia activity includes the production of high levels of anti-inflammatory cytokines like IL-4, IL-10, neurotrophic factors, and proteins such as insulin-like growth factor (IGF)-1, arginase-1 and Ym-1 [144] [145] [146] .
However, the M1 vs. M2 paradigm of macrophage activity has recently been reappraised since it appears to be at odds with the recent data emerging from epigenetics and genome-wide transcriptional studies [112, 147] . New findings have also established that microglia are a unique cell population, distinct from macrophages [112, 148] . Analysis of acutely isolated microglia from SOD1 G93A tg mice revealed upregulation of both neuroprotective and toxic factors related with ALS [112] .
SOD1
G93A microglia upregulated the expression of IGF-1 and progranulin, two microglial factors known to confer neuroprotection and increase survival in ALS models [149, 150] , and progranulin mutations are major known genetic causes of ALS-FTD [151] . With respect to the neurotoxic factors, metalloproteinase 12 and optineurin are upregulated in SOD1 G93A microglia [112] . Mutations in optineurin cause fALS [152, 153] and deregulate interferon signaling [154] , while metalloproteinase inhibition increases survival in ALS mice [155] . More interestingly, in the same study SOD1 G93A microglia also increased the expression of genes related with Alzheimer's, Huntington and Parkinson's diseases but not of genes related with lipopolysaccharide-induced microglial activation [112] .
Thus, the M1-M2 dichotomy does not seem the best-suited concept for explaining the microglial response to motor neuron injury. Rather, microglia become reactive through expression changes in a wide range of genes that mediate the acquisition of new cell functions. This means that, at each moment, the balance of secreted molecules from the 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r R e v i e w O n l y microenvironment determines a spectrum of microglial phenotypes that also vary with the time and intensity of neuron damage [112, 145] . However these phenotypes are classified, microglia respond with a large diversity of signals, some of them detrimental and others restorative, which modulate neuroinflammation and thus interfere with ALS progression (Figure 3 ).
Astrocytes also participate in the inflammatory mechanisms associated with motor neuron degeneration [156] [157] [158] and may play a dual role. Like microglia, astrocytes exert both toxic and protective effects on neurons in a context-dependent manner ( Figure 3) . In fact, they may represent a diverse population of genetically tractable cells that mediate neural circuit-specific roles in health and disease (see [159] for a review). Astrocyte activation has been described in the spinal cord, motor cortex and subcortical white matter [160, 161] of ALS patients. In the SOD1 G93A tg mouse, astrogliosis is concomitant with motor neuron loss [161, 162] .
Astrocytes express MHC molecules and can present antigens to primed memory T cells [163] . They respond to neuronal injury by releasing acute-phase proteins such as α1-antichymotrypsin and α2-macroglobulin, complement proteins, and neuronal growth factors and cytokines [116] . In general, their neurotoxic activity is mediated via activation of pattern recognition receptors such as Toll-like receptors. After receptor activation, astrocytes secrete cytokines like CCL2, IL-6 and other neurotoxic factors that enhance the inflammatory response [108, 164, 165] . Their neuroprotective effects are mediated by an homeostatic control of neuronal activity [159, 166] and the release of neurotrophic factors such as nerve growth factor and IGF-1 [165] .
Astroglia also contribute to motor neuron degeneration through non-immune mechanisms that may be associated with abnormal astrocyte activity rather than with astrogliosis. For example, in ALS patients and in ALS animal models, astroglia lead to [169] . The subsequent increased hemi channel-mediated activity and elevated intracellular calcium levels suggest excessive astrocyte exchange of metabolites, ions and second messengers, which results in an astrocyte-mediated toxic effect on motor neurons.
IS ALS A NEUROINFLAMMATORY DISEASE?
Research into the pathogenesis of ALS had conventionally assumed that neuroinflammation was a response to motor neuron injury and extracellular protein deposition. However, studies in SOD1 tg mice evidenced microglial activation even before motor neuron cell death [170, 171] , which suggested the hypothesis that neuroinflammation might contribute to ALS pathogenesis [107] . Currently, there is increasing evidence linking ALS molecular hallmarks with modifications in microglial activity or the immune system response. For example, TDP-43 and the p65 subunit of the nuclear factor-κB (NF-κB) are increased in the spinal cord of sALS patients when compared with healthy individuals [172] . TDP-43 interacts and co-localizes with p65 in microglia and neurons from ALS patients and mice expressing wild-type and mutant TDP-43 transgenes, but not in cells from healthy individuals or non-transgenic mice [172, 173] . Thus, TDP-43 acts as a co-activator of p65, and microglia expressing larger amounts of TDP-43 produced more pro-inflammatory cytokines and neurotoxic mediators after activation [173] . At the functional level, inhibition of NF-κB activity in TDP-43 mice reduces denervation in the neuromuscular junction and ALS disease 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Similarly, C9orf72 plays a key role in innate immune cell function. Mice lacking C9orf72 develop splenomegaly nad lymphadenopathy and accumulate swollen macrophage-like cells [175] . Loss of C9orf72 in mice also leads to macrophage and microglial dysfunction and age-related neuroinflammation similar to that described in C9orf72 fALS [175] . Again, these new findings raise the possibility of a dual pathogenic mechanism, in which the effects of microglial dysfunction from decreased C9orf72 expression combine with toxic by-products in neurons to promote neurodegeneration ( Figure 2) .
Immune actions may then precede ALS pathology and may be sufficient to cause it, suggesting that ALS is an autoimmune disease. A growing body of evidence supports this hypothesis. For example, circulating myeloid cells of ALS patients have a proinflammatory phenotype [90, 176] , while regulatory T lymphocytes are decreased, enhancing neuroinflammation and disease progression [177] . Also, the up-regulation of inflammatory genes in arrays on samples from ALS patients suggests the involvement of immune actions in the ALS pathogenesis [178] [179] [180] . Some other studies have related motor neuron disease with autoimmune neuromuscular disorders. Around 30% of ALS patients present decrement on repetitive nerve stimulation [181] , and the risk of ALS is increased in people with concomitant myasthenia gravis [182] . This combination of ALS and myasthenia gravis has been reported to occur non-stochastically [183] and, although the reasons for the coincidence are unknown, it may involve a link between the immune system and ALS [156] . Taken together these results suggest that immune processes may drive ALS pathology independently of neural processes, exacerbating motor neuron injury and feeding a cyclic process that sustains neurodegeneration. 21 As in other aspects of the disease, the nature of neuroinflammation in ALS is heterogeneous. In many cases adaptive immune cells may drive the pathological process, a feature that defines ALS as a neuroinflammatory disease rather than a neurodegenerative disorder [139] . However, this concept is far from being consolidated: it remains unclear how and when the immune system impacts the course of ALS, and it stills needs to be clarified whether an immune mechanism is involved in all patients.
MICROGLIA MAY DRIVE ALS PATHOPHYSIOLOGY
A key aspect of CNS function is the dynamic interaction between neurons and microglia. Therefore dysfunction of microglial non-inflammatory activity may contribute to pathological processes [184, 185] . For exemple, excessive activation of microglial CD33 was found to upregulate synapse removal in Alzheimer's disease patiens and mouse models [186, 187] . Also, altered microglial brain-derived neurotrophic factor signaling has been associated with neuropathic pain [123] . In this line, the axis fractalkine-CX3CR1 participates in the control of microglial dysfunction.
Microglial CX3CR1, involved in neurotrophic fuctions, is upregulated in many pathological conditions [188] . The role of CX3CR1 in the control of neuroinflammation has been extensively studied in the CX3CR1-EGFP mouse line. Although the consequences of CX3CR1 deletion in microglia largely depend on the mouse model used, the overall idea is that a lack of CX3CR1 leads to a hyperactivity of microglia in the diseased brain, thereby unleashing potential neurotoxic properties [113, 189, 190] .
However, other evidence suggests that fractalkine sustains neuroinflammation and contributes to neurotoxicity (see [191] for a review). In any case, CX3CR1 signaling impairment has a direct influence on neurodegenerative diseases associated with neuroinflammation, microglia and/or T-cell recruitment [192, 193] . 21 16 In a cohort of Spanish sALS patients, a genetic association was described between the V249I and T280M variants in the human CX3CR1 gene and the progression rate and survival time [34] . This association has also been reported between these two CX3CR1 gene variants and some other inflammatory diseases, including multiple sclerosis, agerelated macular degeneration, AIDS, and coronary disease [194] . V249I and T280M genetic variants affect the activity of the CX3CR1 protein by reducing its affinity to fractalkine [195] . In animal models, CX3CR1-/-knockout mice inbred with the SOD1 G93A tg ALS model present a worsened disease outcome, more extensive neuronal loss and increased microglial activation [196] . As CX3CR1 is involved in microglial neurotrophic function (Figure 3 ), its reduced activity may exacerbate the proinflammatory activity of microglia.
What still remains to be established is whether the fractalkine-CX3CR1 axis is affected in the diseased brain. There are few reports of fractalkine concentration in the brain and CX3CR1 expression in microglia during the course of disease. Cardona et al. [188] detected a rather high concentration of free fractalkine in the brain, which suggests a constitutive release under physiological conditions. In multiple sclerosis or epilepsy, the CNS levels of fractalkine and/or CX3CR1 were found either unchanged or increased [197, 198] , indicating that the inhibitory function of the fractalkine-CX3CR1 axis is not generally weakened under diseased conditions.
Microvesicles (MVs) and exosomes are considered important players in the dynamic interactions between neurons and glia. In the CNS, neurons, microglia, astrocytes and oligodendrocytes release MVs and exosomes with different sizes and contents into the extracellular space. These particles can move freely through the extracellular medium and interact with different cell types by as yet undetermined mechanisms [199] . MVs carry and may shuttle specific proteins and noncoding nucleic acids such as microRNAs [200] . In fact, some miRNA may be found in MVs at higher concentrations than in cells [201] . For these reasons, besides their potential as disease biomarkers [202] , MVs and exosomes are considered to have a role in the pathogenesis and dissemination of inflammatory diseases.
The cell-to-cell transmission of TDP-43 and SOD1 misfolding, which is propagated by prionic mechanisms (see [52] for a review), now appears to be mediated by MVs trafficking. A recent study provides evidence for a primarily microvesicular intercellular spread of TDP-43 aggregates [203] , and both neuronal and astroglial MVs have been implicated in the propagation of pathogenic misfolded SOD1. In vitro, motor neuron NSC-34 cells overexpressing wild type and mutant SOD1 secreted this protein via exosomes [204] . Astrocytes expressing mutant SOD1 release a high amount of exosomes carrying the protein and promote motor neuron death [205] . Interestingly,
MVs from activated astroglia also transfer amino-acid transporter-1 [206] , suggesting a possible role for them in the extracellular mechanism that curtails excitotoxicity.
There is growing evidence of the involvement of miRNA deregulation in ALS pathogenesis [207] [208] [209] [210] [211] . Changes in miRNA expression have been found in patients and the SOD1 G93A mouse [176, 212, 213] reflecting a dysfunction of the expressed RNA binding proteins involved in ALS. miRNAs are stable in cerebrospinal fluid, serum and other body fluids as exosomal cargos [214] and their concentrations are also modified in ALS [215] suggesting that the dysfunction of RNA binding proteins in ALS is systemic.
In serum of fALS patients, specific miRNAs non-related with the mutated gene are downregulated already in presymptomatic disease [216, 217] , whereas serum miRNA profiles are far more heterogeneous in sALS patients [218] . Other exosomal miRNAs are upregulated in ALS [219] . Some are components of the innate immune system and Finally, reactive microglia release MVs and exosomes, which may have a dual role in motor neuron degeneration (Figure 3 ). On the one hand, MVs released by reactive microglia carry pro-inflammatory cytokines [221] and induce an inflammatory reaction in target cells [222] . Microglia-derived MVs also promote precipitation of misfolded proteins in Parkinson's and Alzheimer's disease models [223, 224] . On the other hand, microglia stimulated with interferon-γ release exosomes that confer protection on surrounding cells [225] . Thus, different stimuli may trigger the microglial release of
MVs with different composition and properties, as already described for macrophages and monocytes [226, 227] . If true, microglial activation will lead to increased secretion of MVs, which differ in composition and are associated with ALS pathological processes with distinct roles. This possibility may open up new avenues in the development of treatments for ALS. Currently it is considered that, by engineering MVs, it will be possible to enhance the protective microglial phenotype in order to curtail neuroinflammation and promote tissue repair.
NEUROINFLAMMATION AND ALS TREATMENTS
The difficulty of developing effective treatments for ALS is explained, at least in part, by its heterogeneity and the presence of both functional and structural on-going cell damage. For years, the multiple ALS phenotypes and the identification of many mutations in the SOD1 gene that could not explain the disease were not little help in guiding pharmacological research; riluzole, introduced in 1995, is presently the sole authorized treatment, with limited efficacy and a high financial cost [228] . Since the 1990s, clinical trials with many other drugs have mostly yielded negative results, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60
there is an urgent need to define new and effective therapeutic strategies and improve clinical trials [229] [230] [231] .
Protein aggregation and neuroinflammation are common features of the chronic course of ALS. Therefore the molecular mechanisms underlying these factors are potentially amenable to therapy. In this line, the compound BIIB067, a drug designed to reduce the production of SOD1, is currently in a phase I clinical trial (ClinicalTrials.gov ID:
NCT02623699) [231] . With respect to neuroinflammation some patents protecting the development of anti-inflammatory compounds have been registered for use in ALS [232] , but to our knowledge, none are being developed as part of current ALS therapeutic strategies [231] . In this context, in the search for valid ALS therapies, the standard view of neuroinflammation, which has focused mainly on the cytotoxic activity of microglia, is not longer valid. Instead this view should be replaced by an integrative approach that involves a wide spectrum of microglial phenotypes and recognizes the dynamic interactions between microglia, neurons, immune cells, and astrocytes. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Combinations of the following key words were used: "amyotrophic lateral sclerosis", "ALS", "motor neuron disease", "neuroinflammation", "microglia", "astroglia", "immune system", "excitotoxicity", "environment", "energy metabolism", "nutrition", "risk factor", "phenotype", "neuron-glia interaction"," microvesicle", "exosome", "microRNA".
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Excitotoxicity and glutamateinduced neurodegeneration.
Decreased survival CX3CR1 C-X3-C motif chemokine receptor 1
Receptor for fractalkine, a transmembrane protein and chemokine involved in the adhesion and migration of leukocytes. In the CNS is expressed by microglia and mediates neuron-microglia interactions.
Control of neuroinflammation
Decreased survival KIFAP3 kinesin associated protein 3
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